Evidence map›Paper›PMID 41002874›Full record

ReviewCancer journal (Sudbury, Mass.)

Mitigating the Impact of Drug Shortages in Oncology: Lessons Learned From the 2023 Shortages of Carboplatin and Cisplatin.

Maxwell L Izen, June M McKoy, Linda Martin, Chadi Nabhan, Gretchen LeFever Watson, Joseph Magagnoli, Kenneth R Carson, Kevin Knopf, Edward Smith, Edward Zyszkowski and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maxwell L IzenDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
June M McKoyDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Linda MartinDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Chadi NabhanDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Gretchen LeFever WatsonDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Joseph MagagnoliDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Kenneth R CarsonDivision of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Kevin KnopfSutter Health System, Oakland, CL.
Edward SmithDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Edward ZyszkowskiDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Mia LynchDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Demir UsluDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Peter GeorgantopoulosDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
David AboulafiaThe Floyd and DeLores Jones Cancer Institute at Virginia Mason, Seattle, WA.
Charles L BennettDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC.ORCID 0000-0003-2475-3915

Funding

Research for Adverse Drug-Events And Reports (RADAR)R01CA102713 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WEST, DENNIS PAUL · 2003 to 2010
$3.2M
Southern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine KinaseR01CA165609 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BENNETT, CHARLES L. · 2012 to 2016
$2.2M
Research on Adverse Drug Events and Reports: Novel Multiple Myeloma DrugsR01CA125077 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WEST, DENNIS PAUL · 2007 to 2009
$1.7M
NCI NIH HHS R01 CA102713NCI NIH HHS R01 CA125077NCI NIH HHS R01 CA165609
6 · The paper itself

Abstract

PURPOSE/

backgroundCancer drug shortages adversely affect cancer patient care and ultimately cancer patient lives. Shortages of cancer drugs used for pediatric cancer patients are well described.

methodsReview of published literature, news reports, and grey literature on cisplatin and carboplatin shortages.

resultsThe shortages were multifactorial-reflecting supply chain disruption, limited redundancy in manufacturing, and dependence on out-of-country sources for injectable generic oncology drugs. DISCUSSION: This report of carboplatin and cisplatin shortages extends concerns noted earlier with pediatric oncology drug shortages. Improvements in supply chain and consideration of on-shoring manufacturing is needed.

Indexed as

Antineoplastic AgentsCarboplatinCisplatinNeoplasmsDrugs, GenericHumansMedical OncologyAntineoplastic AgentsCarboplatinCisplatinDrugs, Genericcancer drugscarboplatin cisplatinoncology drug shortagesshortages

Identifiers

PMID41002874
PMCPMC12724352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.